Several inhibitors of the TGFβ pathway are being developed and clinically tested for a number of cancers, including glioma, pancreatic cancer, non-small-cell lung carcinoma, advanced HCC and melanoma [158], [159], [160], [161]. The gene discussed is TGFB1; the disease is central nervous system cancer.